What agents use the Wnt pathway as a target for cancer?
Site of intervention used depends on the mutation
Top of pathway (ligand, receptor)
Wnt ligand and receptor inhibitors, e.g. mAbs, Porcupine inhibitors (decrease Wnt ligand secretion)
Use when Wnt ligand/receptor is overexpressed
Further down pathway (B-catenin destruction complex)
Axin inhibitors, e.g. tankyrase (PARP inhibitors)
Targeting axin (as part of the complex) may help in absence of APC
Bottom of pathway (B-catenin)